Pharsight

Drugs that contain Testosterone Undecanoate

1. Aveed patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Mar, 2027

(3 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
May, 2027

(3 years from now)

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: INJECTABLE;INTRAMUSCULAR

How can I launch a generic of AVEED before it's drug patent expiration?
More Information on Dosage

AVEED family patents

Family Patents

2. Jatenzo patents expiration

JATENZO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11179402 CLARUS Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Apr, 2026

(2 years from now)

US10617696 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11331325 CLARUS Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Jan, 2027

(2 years from now)

US8241664 CLARUS Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Mar, 2029

(5 years from now)

US8778916 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(6 years from now)

US11426416 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(6 years from now)

US11179403 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(6 years from now)

US10543219 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(6 years from now)

US8492369 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 27, 2022

Market Authorisation Date: 27 March, 2019

Treatment: Method of treating testosterone deficiency; A method of treating testosterone deficiency in men

Dosage: CAPSULE;ORAL

More Information on Dosage

JATENZO family patents

Family Patents

3. Jatenzo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564933 TOLMAR Methods of treating testosterone deficiency
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 27, 2022

Market Authorisation Date: 27 March, 2019

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: CAPSULE;ORAL

More Information on Dosage

JATENZO family patents

Family Patents

4. Kyzatrex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10576090 MARIUS PHARMS LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Dec, 2030

(6 years from now)

US11590146 MARIUS PHARMS LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Dec, 2030

(6 years from now)

US10576089 MARIUS PHARMS LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Dec, 2030

(6 years from now)

US11617758 MARIUS PHARMS LLC Emulsion formulations
Mar, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jul 27, 2025

Market Authorisation Date: 27 July, 2022

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

KYZATREX family patents

Family Patents

5. Tlando patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778922 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(4 years from now)

US11304960 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(4 years from now)

US8865695 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(4 years from now)

US10226473 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US10716794 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US9949985 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11311555 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US9943527 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11433083 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11364249 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11559530 ANTARES PHARMA INC Oral testosterone undecanoate therapy
Nov, 2037

(13 years from now)

US11464735 ANTARES PHARMA INC Fixed dose oral testosterone undecanoate compositions and use thereof
Apr, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 28, 2025

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: CAPSULE;ORAL

More Information on Dosage

TLANDO family patents

Family Patents